Patient advocates, biopharma lobbyists are pushing to revive PRVs

Indiana-based developer of long-acting peptide therapeutics is latest mid-to-late-stage biotech to seek NASDAQ listing

An IR/PR pioneer, Burns connected CEOs, investors and analysts and played host to JPM’s best party

Arch backs immunology/fibrosis start-up; JHU spinout launches with $150M; San Diego-based pair advance clinical plans in oncology and neuroscience

As more companies bring IL-18 into their cancer pipelines, they also bring new modalities and approaches to the cytokine’s inhibitory decoy receptor

Deal for $4.8B up front includes $1B contingent value right associated with milestone for PRMT5 program

Plus: Emerson Collective spins out Yosemite with $200M cancer fund, first commercial patient receives Sarepta’s DMD gene therapy, and more

Elevidys highlights need for clearer criteria for accelerated approval of therapies for rare diseases

Patient groups, industry support anti-QALY bill; ICER, consumer groups oppose it

Passed 40 years ago, it may be time for ODA 2.0